Investor Relations


Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidates are first-in-class treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

Recent News

October 7, 2019
  LEXINGTON, Mass. --(BUSINESS WIRE)--Oct. 7, 2019-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady , M.D., Ph.D., President and CEO of Aldeyra, will present on Thursday, October 10 at the Ophthalmology Innovation Summit (OIS) at the American Academy of ...
September 26, 2019
  LEXINGTON, Mass. --(BUSINESS WIRE)--Sep. 26, 2019-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will host an ePoster presentation and discussion of the company’s ALLEVIATE Phase 3 clinical trial of reproxalap in patients with allergic conjunctivitis at the American ...
View All

Contact Us

Investor Relations Contact 

Scott Solomon
Sharon Merrill Associates
Senior Vice President
PHONE: 857-383-2409